CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 4 indication-specific expa...
Phase 1, Phase 2
Philadelphia, Pennsylvania, United States and 56 other locations
in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that...
Phase 1
Philadelphia, Pennsylvania, United States and 7 other locations
NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted standard treatment, includi...
Phase 1
Newark, Delaware, United States and 6 other locations
Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Par...
Phase 1
Philadelphia, Pennsylvania, United States and 10 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...
Phase 2
Philadelphia, Pennsylvania, United States and 43 other locations
chemotherapy in induction-eligible patients with acute myeloid leukemia.This study involves the following:* Venetoclax and azacitidine (inve...
Phase 2
Philadelphia, Pennsylvania, United States and 8 other locations
This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogene...
Phase 1
Philadelphia, Pennsylvania, United States
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL...
Phase 1, Phase 2
Philadelphia, Pennsylvania, United States and 9 other locations
People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes l...
Phase 1, Phase 2
Philadelphia, Pennsylvania, United States and 19 other locations
The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs....
Phase 1, Phase 2
Philadelphia, Pennsylvania, United States and 38 other locations
Clinical trials
Research sites
Resources
Legal